Kodiak Sciences stock saw significant rise over 150% at the opening bell after its drugs successfully passed a key trial. The stock continued to rise, doubling in value as the new eye disease drug matched up with Eylea in a phase 3 trial. Additional reports indicated the stock gained 172% as Kodiak's drugs targeted Regeneron's Eylea. The company's stock price skyrocketed toward $100 following strong phase 3 key trial data for wet AMD.
More Top Stories
Charlie Sheen's aide convicted of assaulting two girls
A man claiming to be Charlie Sheen's personal assistant has been convicted of assaulting two girls. The case i...
The 2026 NRL Grand Final tickets are now for sale
Tickets for the 2026 NRL Grand Final are now available. Tickets for the event can be purchased through NRL.com...
Noah Woods: Community Mourns After Playground Tragedy
A three year old boy named Noah Woods passed away after being at a playground. He managed to a gap in a fence...
Taylor Townsend's historic win at the US Open 2026
Taylor Townsend shared that her relationship with Serena Williams has changed. She recently achieved a histori...
The Saints face off against the Raiders in a highly anticipated game
Raiders tight end Brock Bowers is expected to play in the upcoming game against the Saints. Chris Olave leads...
Gloucester City Council Leader Voted Out
Jeremy Hilton has been voted out as leader of the Gloucester City Council following a no confidence vote. The...
Weekly Review · News Roundup · Weekly Review · Weekly Review · Local Briefing · Latest Update · Weekly Review · News Roundup · Community Report · Community Report · Weekly Review · Weekly Review · Latest Update · Latest Update · Local Briefing · Latest Update · Community Report · Latest Update · News Roundup · News Roundup · Local Briefing · Daily Digest · Local Briefing · Daily Digest · Weekly Review · Daily Digest · Latest Update · Latest Update · News Roundup · Latest Update · Weekly Review · News Roundup · Daily Digest · Community Report · Community Report · Community Report · News Roundup · Community Report · Weekly Review · Latest Update